UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORX):
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013.
Zubsolv® evolution continues. 81 percent increase in Zubsolv tablets prescribed compared to previous quarter.
Help employers find you! Check out all the jobs and post your resume.
